EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gubra AS's EBITDA for the
six
months ended in Dec. 2025 was €-24.9 Mil. Gubra AS's Revenue for the
six
months ended in Dec. 2025 was €19.4 Mil. Therefore, Gubra AS's EBITDA margin for the quarter that ended in Dec. 2025 was -128.31%.
Gubra AS (STU:PI3) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gubra AS EBITDA Margin % Related Terms
Gubra AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gubra AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PI3 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Gubra AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gubra AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (STU:PI3) has a EBITDA Margin % of -128.31% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gubra AS and its competitors. According to the industry distribution chart, Gubra AS ranks #24 out of 945 companies in the Biotechnology industry, placing it in the top 2.5%.
Is Gubra AS's EBITDA Margin % too high?
Gubra AS's current EBITDA Margin % is -128.31%. Based on the distribution chart, Gubra AS ranks #24 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gubra AS has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #24 out of 945 companies for EBITDA Margin %. This places Gubra AS in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gubra AS and its competitors. Gubra AS's current EBITDA Margin % is -128.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (STU:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €381.21, compared to a current price of €44.22 — trading 88.4% below its estimated fair value. The current EBITDA Margin % is -128.31%. Gubra AS's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gubra AS (STU:PI3), the current EBITDA Margin % is -128.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (STU:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €44.22 is trading 88.4% below its estimated GF Value™ of €381.21.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for STU:PI3:
EBITDA Margin %: -128.31%
GF Value™: €381.21 vs. price of €44.22 (88.4% below fair value)
No single metric tells the full story. See the STU:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
58GF Score
Get the complete analysis for STU:PI3
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PI3 has been successfully added to your 
